24HR viloxazine 200 mg Extended Release Oral Capsule
RxNorm 2536756
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2536756 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: 24HR viloxazine 200 mg Extended Release Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
24 HR viloxazine 200 mg Extended Release Oral Capsule
(Atom ID: 12624137)
PSNPrescribable
Prescribable Name (PSN):
24HR viloxazine 200 mg Extended Release Oral Capsule
(Atom ID: 12624146)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely viloxazine (as viloxazine hydrochloride) 200 mg/1 each prolonged-release oral capsule (clinical drug)
(Atom ID: 12727582)
PTPrescribable
Designated preferred name (PT):
Viloxazine (as viloxazine hydrochloride) 200 mg prolonged-release oral capsule
(Atom ID: 12728038)
Patient Education
Viloxazine
Viloxazine is used as part of a total treatment program to increase the ability to pay attention and decrease impulsiveness and hyperactivity in children 6 to 17 years of age with attention deficit hyperactivity disorder (ADHD). Viloxazine is in a class of medications called selective norepinephrine reuptake inhibitors. It works by increasing the levels of norepinephrine, a natural substance in the brain that is needed to control behavior.
[Learn More]
* Please review the disclaimer below.